USD fixed-income securities

Issuer Amount (in millions) Coupon Maturity
Novartis Capital Corp. 2,150 3.400% 2024
Novartis Capital Corp. 1,000 1.750% 2025
Novartis Capital Corp. 1,750 3.000% 2025
Novartis Capital Corp. 1,250 2.000% 2027
Novartis Capital Corp. 1,000 3.100% 2027
Novartis Capital Corp. 1,500 2.200% 2030
Novartis Capital Corp. 500 3.700% 2042
Novartis Capital Corp. 1,850 4.400% 2044
Novartis Capital Corp. 1,250 4.000% 2045
Novartis Capital Corp. 1,250 2.750% 2050

Credit ratings of Novartis AG

  Moody’s Investors Service S&P Global Ratings
Short term P-1 A-1+
Long term A1 AA-
Outlook Stable Stable

Novartis Capital Corp.

Principal amount USD 2,150,000,000
ISIN US66989HAG39
Issuer Novartis Capital Corp., United States
Guarantor Novartis AG, Switzerland
Type Senior unsecured
Coupon 3.400%
Coupon payment date May 6 and November 6, commencing May 6, 2014
Documentation SEC registered shelf registration
First settlement date February 21, 2014
Issue price 99.287
Maturity date May 6, 2024
Joint book-runners Goldman Sachs, Bank of America Merrill Lynch, Barclays, Citi, Credit Suisse, Deutsche Bank, JP Morgan
Bloomberg NOVNVX 3.4 05/06/24

Novartis Capital Corp.

Principal amount USD 1,000,000,000
ISIN US66989HAP38
Issuer Novartis Capital Corp., United States
Guarantor Novartis AG, Switzerland
Type Senior unsecured
Coupon 1.750%
Coupon payment date February 14 and August 14, commencing August 14, 2020
Documentation SEC registered shelf registration
First settlement date February 14, 2020
Issue price 99.852
Maturity date February 14, 2025
Joint book-runners Citi, HSBC, Morgan Stanley, Mitsubishi UFJ Financial Group, Barclays, Deutsche Bank, Mizuho
Bloomberg NOVNVX 1.75 02/14/2025

Novartis Capital Corp.

Principal amount USD 1,750,000,000
ISIN US66989HAJ77
Issuer Novartis Capital Corp., United States
Guarantor Novartis AG, Switzerland
Type Senior unsecured
Coupon 3.000%
Coupon payment date May 20 and November 20, commencing May 20, 2016
Documentation SEC registered shelf registration
First settlement date November 20, 2015
Issue price 99.010
Maturity date November 20, 2025
Joint book-runners Bank of America Merrill Lynch, Citi, JP Morgan, Credit Suisse, Goldman Sachs, UBS
Bloomberg NOVNVX 3 11/20/2025

Novartis Capital Corp.

Principal amount USD 1,250,000,000
ISIN US66989HAQ11
Issuer Novartis Capital Corp., United States
Guarantor Novartis AG, Switzerland
Type Senior unsecured
Coupon 2.000%
Coupon payment date February 14 and August 14, commencing August 14, 2020
Documentation SEC registered shelf registration
First settlement date February 14, 2020
Issue price 99.909
Maturity date February 14, 2027
Joint book-runners Citi, HSBC, Morgan Stanley, Mitsubishi UFJ Financial Group, Barclays, Deutsche Bank, Mizuho
Bloomberg NOVNVX 2.0 02/14/2027

Novartis Capital Corp.

Principal amount USD 1,000,000,000
ISIN US66989HAN89
Issuer Novartis Capital Corp., United States
Guarantor Novartis AG, Switzerland
Type Senior unsecured
Coupon 3.100%
Coupon payment date May 17 and November 17, commencing May 17, 2017
Documentation SEC registered shelf registration
First settlement date February 17, 2017
Issue price 99.109
Maturity date May 17, 2027
Joint book-runners Bank of America Merrill Lynch, Citi, JP Morgan, Credit Suisse, Goldman Sachs, UBS
Bloomberg NOVNVX 3.1 05/17/2027

Novartis Capital Corp.

Principal amount USD 1,500,000,000
ISIN US66989HAR93
Issuer Novartis Capital Corp., United States
Guarantor Novartis AG, Switzerland
Type Senior unsecured
Coupon 2.200%
Coupon payment date February 14 and August 14, commencing August 14, 2020
Documentation SEC registered shelf registration
First settlement date February 14, 2020
Issue price 99.869
Maturity date August 14, 2030
Joint book-runners Citi, HSBC, Morgan Stanley, Mitsubishi UFJ Financial Group, Barclays, Deutsche Bank, Mizuho
Bloomberg NOVNVX 2.2 08/14/2030

Novartis Capital Corp.

Principal amount USD 500,000,000
ISIN US66989HAF55
Issuer Novartis Capital Corp., United States
Guarantor Novartis AG, Switzerland
Type Senior unsecured
Coupon 3.700%
Coupon payment date March 21 and September 21, commencing March 21, 2013
Documentation SEC registered shelf registration
First settlement date September 21, 2012
Issue price 98.325
Maturity date September 21, 2042
Joint book-runners JP Morgan, Morgan Stanley, BNP Paribas, Citi, Bank of America Merrill Lynch, UBS
Bloomberg NOVNVX 3.7 09/21/42

Novartis Capital Corp.

Principal amount USD 1,850,000,000
ISIN US66989HAH12
Issuer Novartis Capital Corp., United States
Guarantor Novartis AG, Switzerland
Type Senior unsecured
Coupon 4.400%
Coupon payment date May 6 and November 6, commencing May 6, 2014
Documentation SEC registered shelf registration
First settlement date February 21, 2014
Issue price 99.196
Maturity date May 6, 2044
Joint book-runners Goldman Sachs, Bank of America Merrill Lynch, Barclays, Citi, Credit Suisse, Deutsche Bank, JP Morgan
Bloomberg NOVNVX 4.4 05/06/44

Novartis Capital Corp.

Principal amount USD 1,250,000,000
ISIN US66989HAK41
Issuer Novartis Capital Corp., United States
Guarantor Novartis AG, Switzerland
Type Senior unsecured
Coupon 4.000%
Coupon payment date May 20 and November 20, commencing May 20, 2016
Documentation SEC registered shelf registration
First settlement date November 20, 2015
Issue price 98.029
Maturity date November 20, 2045
Joint book-runners Bank of America Merrill Lynch, Citi, JP Morgan, Credit Suisse, Goldman Sachs, UBS
Bloomberg NOVNVX 4 11/20/2045

Novartis Capital Corp.

Principal amount USD 1,250,000,000
ISIN US66989HAS76
Issuer Novartis Capital Corp., United States
Guarantor Novartis AG, Switzerland
Type Senior unsecured
Coupon 2.750%
Coupon payment date February 14 and August 14, commencing August 14, 2020
Documentation SEC registered shelf registration
First settlement date February 14, 2020
Issue price 97.712
Maturity date August 14, 2050
Joint book-runners Citi, HSBC, Morgan Stanley, Mitsubishi UFJ Financial Group, Barclays, Deutsche Bank, Mizuho
Bloomberg NOVNVX 2.75 08/14/2050

CHF fixed-income securities

Issuer Amount (in millions) Coupon Maturity
Novartis AG 500 0.250% 2025
Novartis AG 550 0.625% 2029
Novartis AG 325 1.050% 2035

Credit ratings of Novartis AG

  Moody’s Investors Service S&P Global Ratings
Short term P-1 A-1+
Long term A1 AA-
Outlook Stable Stable

Novartis AG

Principal amount CHF 500,000,000
ISIN CH0270190983
Issuer Novartis AG, Switzerland
Type Senior unsecured
Coupon 0.250%
Coupon payment date May 13
Documentation Swiss stand-alone documentation
First settlement date February 13, 2015
Issue price 100.640
Maturity date May 13, 2025
Joint book-runners Credit Suisse, UBS
Bloomberg NOVNVX 0.25 05/13/25
Listing SIX Swiss Exchange

Novartis AG

Principal amount CHF 550,000,000
ISIN CH0270190991
Issuer Novartis AG, Switzerland
Type Senior unsecured
Coupon 0.625%
Coupon payment date November 13
Documentation Swiss stand-alone documentation
First settlement date February 13, 2015
Issue price 100.502
Maturity date November 13, 2029
Joint book-runners Credit Suisse, UBS
Bloomberg NOVNVX 0.625 11/13/29
Listing SIX Swiss Exchange

Novartis AG

Principal amount CHF 325,000,000
ISIN CH0270191007
Issuer Novartis AG, Switzerland
Type Senior unsecured
Coupon 1.050%
Coupon payment date May 11
Documentation Swiss stand-alone documentation
First settlement date February 13, 2015
Issue price 100.479
Maturity date May 11, 2035
Joint book-runners Credit Suisse, UBS
Bloomberg NOVNVX 1.05 05/11/35
Listing SIX Swiss Exchange

EUR fixed-income securities

Issuer Amount (in millions) Coupon Maturity
Novartis Finance S.A. 750 0.500% 2023
Novartis Finance S.A. 1,250 0.125% 2023
Novartis Finance S.A. 600 1.625% 2026
Novartis Finance S.A. 600 1.125% 2027
Novartis Finance S.A. 500 0.625% 2028
Novartis Finance S.A. 1,850 0.000% 2028
Novartis Finance S.A. 750 1.375% 2030
Novartis Finance S.A. 750 1.700% 2038

Credit ratings of Novartis AG

  Moody’s Investors Service S&P Global Ratings
Short term P-1 A-1+
Long term A1 AA-
Outlook Stable Stable

Novartis Finance S.A.

Principal amount EUR 750,000,000
ISIN XS1769040111
Issuer Novartis Finance S.A., Luxembourg
Guarantor Novartis AG, Switzerland
Type Senior unsecured
Coupon 0.500%
Coupon payment date August 14
Documentation Standalone
First settlement date February 14, 2018
Issue price 99.655
Maturity date August 14, 2023
Joint book-runners Barclays, BNP Paribas, Deutsche Bank
Bloomberg NOVNVX 0.5 08/14/23
Listing SIX Swiss Exchange

Novartis Finance S.A.

Principal amount EUR 1,250,000,000
ISIN XS1492825051
Issuer Novartis Finance S.A., Luxembourg
Guarantor Novartis AG, Switzerland
Type Senior unsecured
Coupon 0.125%
Coupon payment date September 20
Documentation Standalone
First settlement date September 20, 2016
Issue price 99.127
Maturity date September 20, 2023
Joint book-runners Barclays, BNP Paribas, Deutsche Bank
Bloomberg NOVNVX 0.125 09/20/23
Listing SIX Swiss Exchange

Novartis Finance S.A.

Principal amount EUR 600,000,000
ISIN XS1134729794
Issuer Novartis Finance S.A., Luxembourg
Guarantor Novartis AG, Switzerland
Type Senior unsecured
Coupon 1.625%
Coupon payment date November 09
Documentation Standalone
First settlement date November 07, 2014
Issue price 99.697
Maturity date November 09, 2026
Joint book-runners Barclays, BNP Paribas, Deutsche Bank
Bloomberg NOVNVX 1.625 11/09/26
Listing SIX Swiss Exchange

Novartis Finance S.A.

Principal amount EUR 600,000,000
ISIN XS1585010074
Issuer Novartis Finance S.A., Luxembourg
Guarantor Novartis AG, Switzerland
Type Senior unsecured
Coupon 1.125%
Coupon payment date September 30, commencing September 30, 2017
Documentation Standalone
First settlement date March 31, 2017
Issue price 99.874
Maturity date September 30, 2027
Joint book-runners Barclays, BNP Paribas, Deutsche Bank
Bloomberg NOVNVX 1.125 09/30/27
Listing SIX Swiss Exchange

Novartis Finance S.A.

Principal amount EUR 500,000,000
ISIN XS1492825481
Issuer Novartis Finance S.A., Luxembourg
Guarantor Novartis AG, Switzerland
Type Senior unsecured
Coupon 0.625%
Coupon payment date September 20
Documentation Standalone
First settlement date September 20, 2016
Issue price 98.48
Maturity date September 20, 2028
Joint book-runners Barclays, BNP Paribas, Deutsche Bank
Bloomberg NOVNVX 0.625 09/20/28
Listing SIX Swiss Exchange

Novartis Finance S.A.

Principal amount EUR 1,850,000,000
ISIN XS2235996217
Issuer Novartis Finance S.A., Luxembourg
Guarantor Novartis AG, Switzerland
Type Senior unsecured
Coupon 0.000%
Coupon step-up Coupon to increase by 25 basis points from 2026 onwards if Novartis does not achieve the 2025 Patient Access Targets
Coupon payment date September 23
Documentation Standalone
First settlement date September 23, 2020
Issue price 99.354
Maturity date September 23, 2028
Joint book-runners Barclays, HSBC, J.P. Morgan, Societe Generale
Bloomberg NOVNVX 0 09/23/28
Listing SIX Swiss Exchange

Novartis Finance S.A.

Principal amount EUR 750,000,000
ISIN XS1769041192
Issuer Novartis Finance S.A., Luxembourg
Guarantor Novartis AG, Switzerland
Type Senior unsecured
Coupon 1.375%
Coupon payment date August 14
Documentation Standalone
First settlement date February 14, 2018
Issue price 99.957
Maturity date August 14, 2030
Joint book-runners Barclays, BNP Paribas, Deutsche Bank
Bloomberg NOVNVX 1.375 08/14/30
Listing SIX Swiss Exchange

Novartis Finance S.A.

Principal amount EUR 750,000,000
ISIN XS1769041606
Issuer Novartis Finance S.A., Luxembourg
Guarantor Novartis AG, Switzerland
Type Senior unsecured
Coupon 1.700%
Coupon payment date August 14
Documentation Standalone
First settlement date February 14, 2018
Issue price 99.217
Maturity date August 14, 2038
Joint book-runners Barclays, BNP Paribas, Deutsche Bank
Bloomberg NOVNVX 1.7 08/14/38
Listing SIX Swiss Exchange

Disclaimer: The information provided on this website does not constitute investment advice, or an offer of, or an invitation or solicitation by, or on behalf of, Novartis AG or any of its subsidiaries, to subscribe for, purchase or sell any securities, including any of the securities described above and below. The information provided also does not constitute an offer, and may not be used for the purpose of an offer to, or a solicitation by, anyone in any jurisdiction or in any circumstances in which such an offer or solicitation is not authorized or is unlawful. You should always seek advice to determine whether governing law permits the use or possession of the information provided.

Neither Novartis AG, nor any of its subsidiaries or employees accepts any liability for any direct or consequential loss arising from any use of the information provided. In particular, neither Novartis AG, nor any of its subsidiaries or employees accepts any liability for any third party content that may be viewed on this site. All information provided is also qualified in its entirety by reference to the relevant prospectuses, supplemental information and other documentation related to the securities described above and below.